Business
Medicenna to Present at Jones Healthcare and Technology Innovation Conference
TORONTO and HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (&...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"Medicenna to Present at Jones Healthcare and Technology Innovation Conference\n\n\n\n TORONTO and HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, today announced that Dr. Fahar Merchant, President and CEO of Medicenna, will present and participate in one-on-one meetings at the Jones Healthcare and Technology Innovation Conference, to be held April 8-9, 2025 in Las Vegas, Nevada.\n \n\n\n Details on the presentation are as follows:\n \n\n\n Date:\n \n Wednesday, April 9, 2025\n \n\n Time:\n \n 2:00 p.m. Pacific Time\n \n\n Location:\n \n The Venetian Resort in Las Vegas, Nevada\n \n\n Webcast and replay information for this event will be available on the Investor Relations section of Medicenna's website at\n \n ir.medicenna.com\n \n . The replay will be available for 90 days.\n \n\n The Jones Healthcare and Technology Innovation Conference is recognized for bringing together a select group of innovative companies and institutional investors for a two-day event. The event will be focused on one-on-one meetings, presentations, fireside chats, panels, and networking.\n \n\n\n About Medicenna Therapeutics\n \n\n\n Medicenna is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Medicenna’s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Medicenna’s IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in 5 clinical trials enrolling over 130 patients, including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively. Medicenna’s early-stage high-affinity IL-2β biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. ...